Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teriparatide Nasal Spray in Postmenopausal Women with Low BMD
NCT00624481Phase 2Withdrawn
- Sponsor
- Nastech Pharmaceutical Company Inc.
- Start
- Mar 2008
- Primary completion
- Apr 2009
- Modality
- Peptides
01
Overview
Phase 2, randomised, open-label trial of Osteofortil in osteoporosis and osteopenia, sponsored by Nastech Pharmaceutical Company Inc. Planned start Mar 2008; status: withdrawn.
02
Drugs
Osteofortil
03
Conditions
osteoporosisosteopenia
Beyond the preview
Go deeper on NCT00624481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00624481.